DexCom, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2025: 23.51%

DexCom, Inc. EBITDA Margin is 23.51% for the Trailing 12 Months (TTM) ending March 31, 2025, a -10.23% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.
  • DexCom, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2024 was 26.19%, a 32.25% change year over year.
  • DexCom, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2023 was 19.80%, a 30.84% change year over year.
  • DexCom, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2022 was 15.13%, a -21.94% change year over year.
  • DexCom, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2021 was 19.39%, a 16.75% change year over year.
Key Data
Date EBITDA Margin Net Income Margin EBT Margin Operating Income Margin